| Literature DB >> 30375420 |
Rwei-Ling Yu1,2,3,4, Po See Chen1,2, Shao-Ching Tu5, Wei-Chia Tsao6, Chun-Hsiang Tan7,8.
Abstract
The neuropathology of Parkinson's disease (PD) involves the frontal-subcortical circuit, an area responsible for processing affective theory of mind (ToM). Patients with PD are expected to experience deficits in the affective ToM. This study aims to investigate whether the ability to infer emotion in others is affected in either young-onset Parkinson's disease (YOPD) or middle-onset PD (MOPD) patients and to test whether the impairments in affective ToM are associated with the motor symptoms. The affective ToM, global mental abilities, and clinical symptoms were assessed in a total of 107 MOPD, 30 YOPD, and 30 normal controls (NCs). The MOPD patients exhibited deficits in affective ToM to the negative and neutral valences, when compared to the participants in the NCs and YOPD group. By conducting gender-stratified analysis, the deficits in affective ToM was only found in female participants. After adjusting for demographic variables, the multiple linear regression model revealed that affective ToM predicted motor symptoms, especially in female MOPD patients. The present study may aid in the development of medical care programs by advocating for a more comprehensive therapeutic plan that includes continuous disease progression monitoring and social skills training for female MOPD patients or their caregivers.Entities:
Mesh:
Year: 2018 PMID: 30375420 PMCID: PMC6207749 DOI: 10.1038/s41598-018-33988-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic Characteristics and Mental State of the Study Groups.
| NCs (n = 30) | YOPD (n = 30) | MOPD (n = 30) | Stat. Value | P-value | Post Hoc | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Range | Mean | SD | Range | Mean | SD | Range | ||||
| Gender, F/M | 19/11 | — | — | 13/17 | — | — | 14/16 | — | — | 2.75a | 0.252 | n.s. |
| Education, y | 12.05 | 4.14 | 3–18 | 12.76 | 3.13 | 6–16 | 12.40 | 3.36 | 6–16 | 0.412c | 0.814 | n.s. |
| Age, y | 58.66 | 7.12 | 51–75 | 53.22 | 5.29 | 41–63 | 61.40 | 5.43 | 54–75 | 25.104c | <0.001 | YOPD < NCs = MOPD |
| Age of onset, y | — | — | — | 45.01 | 3.97 | 36–49 | 54.93 | 3.83 | 50–63 | <0.001b | <0.001 | YOPD < MOPD |
| MMSE | 28.20 | 1.66 | 24–30 | 29.06 | 1.14 | 25–30 | 28.56 | 1.27 | 25–30 | 5.645c | 0.059 | n.s. |
| Disease duration, y | — | — | — | 8.13 | 4.58 | 0.66–17 | 6.43 | 3.79 | 2–16 | 348.50b | 0.132 | n.s. |
| H&Y stage | — | — | — | 2.30 | 0.95 | 1–4 | 2.30 | 0.83 | 1–4 | 445.50b | 0.944 | n.s. |
| LED | — | — | — | 918.26 | 522.04 | 120–2196 | 699.87 | 438.01 | 200–1830 | 332.00b | 0.081 | n.s. |
| MDS-UPDRS | ||||||||||||
| nM-EDL | — | — | — | 9.03 | 6.48 | 0–29 | 8.64 | 5.23 | 1–24 | 384.50b | 0.902 | n.s. |
| motor-EDL | — | — | — | 12.46 | 8.70 | 0–29 | 10.86 | 7.32 | 0–30 | 376.50b | 0.637 | n.s. |
| MEx | — | — | — | 26.50 | 12.50 | 5–46 | 30.32 | 15.03 | 7–65 | 0.789d | 0.306 | n.s. |
Abbreviations: NCs, normal controls; YOPD, young-onset Parkinson’s disease; MOPD, middle-onset Parkinson’s disease; SD, standard deviation; n.s., not significant; H&Y, Hoehn and Yahr; MDS-UPDRS, Movement Disorder Society–Unified Parkinson’s Disease Rating Scale; nM-EDL, non-motor experiences of daily living; motor-EDL, motor experiences of daily living; MEx, motor function; LED, levodopa equivalent dose; MMSE, Mini-Mental State Examination.
achi-square test; bMann-Whitney U test; cKruskal-Wallis test; dT-test.
Figure 1The distribution of the RMET scores in the study groups (Normal = 30, YOPD = 30, MOPD = 30). Mean values and standard error of the mean (SEM, vertical bars) of RMET total score and three valence (e.g., positive, negative, neutral) scores in the three study groups. YOPD, young-onset Parkinson’s disease; MOPD, middle-onset Parkinson’s disease. *P-value < 0.05. **P-value < 0.01.
Gender-stratified analysis of the RMET.
| NCs | YOPD | MOPD | Stat. Value | P-value | Post Hocc | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Range | Mean | SD | Range | Mean | SD | Range | ||||
| RMET in males | 19.45 | 4.11 | 15–29 | 20.88 | 4.53 | 12–29 | 18.81 | 5.00 | 6–27 | 0.870a | 0.428 | n.s. |
| Positive valence | 3.36 | 1.75 | 1–6 | 4.24 | 2.02 | 0–7 | 4.06 | 2.05 | 0–7 | 0.690a | 0.505 | n.s. |
| Negative valence | 6.36 | 2.34 | 3–10 | 6.47 | 1.84 | 2–9 | 5.69 | 1.82 | 3–9 | 1.872b | 0.392 | n.s. |
| Neutral valence | 9.73 | 2.41 | 6–14 | 10.18 | 2.21 | 6–14 | 9.06 | 3.13 | 3–15 | 0.740a | 0.481 | n.s. |
| RMET in females | 22.53 | 2.93 | 17–30 | 23.31 | 3.90 | 16–30 | 17.00 | 3.16 | 10–21 | 15.510a | <0.001 | NCs = YOPD > MOPD |
| Positive valence | 4.42 | 1.39 | 2–7 | 4.46 | 1.56 | 2–7 | 3.64 | 1.39 | 2–6 | 1.490a | 0.237 | n.s. |
| Negative valence | 7.58 | 1.46 | 5–10 | 7.77 | 2.24 | 4–12 | 5.07 | 1.98 | 1–8 | 9.380a | <0.001 | NCs = YOPD > MOPD |
| Neutral valence | 10.53 | 2.14 | 7–14 | 11.08 | 2.02 | 8–15 | 8.29 | 1.44 | 6–10 | 8.340a | 0.001 | NCs = YOPD > MOPD |
Abbreviations: see Table 1 and RMET, reading the mind in the eye test.
aANOVA; one-way analysis of variance.
bKruskal-Wallis test.
cScheffe post-hoc test.
Figure 2Correlations between the RMET total score and specific motor symptoms.
Multiple linear regression analyses in all MOPD participants and stratified by gender.
| Independent variable | Total (n = 107) | Male (n = 64) | Female (n = 43) | |||
|---|---|---|---|---|---|---|
| ß ± SEa | p-value | ß ± SEb | p-value | ß ± SEb | p-value | |
| nM-EDL (dependent variable) | ||||||
| RMET total scores | −0.03 ± 0.02 | 0.06 | −0.03 ± 0.02 | 0.15 | −0.04 ± 0.03 | 0.18 |
| Positive valence scores | −0.06 ± 0.04 | 0.13 | −0.05 ± 0.04 | 0.26 | −0.06 ± 0.07 | 0.37 |
| Negative valence scores | −0.05 ± 0.04 | 0.15 | −0.05 ± 0.04 | 0.30 | −0.09 ± 0.07 | 0.20 |
| Neutral valence scores | −0.04 ± 0.03 | 0.24 | −0.04 ± 0.04 | 0.32 | −0.05 ± 0.06 | 0.44 |
| motor-EDL (dependent variable) | ||||||
| RMET total scores | −0.26 ± 0.12 | 0.04* | −0.15 ± 0.15 | 0.32 | −0.47 ± 0.23 | 0.05 |
| Positive valence scores | −0.48 ± 0.29 | 0.10 | −0.53 ± 0.34 | 0.13 | −0.27 ± 0.56 | 0.64 |
| Negative valence scores | −0.62 ± 0.28 | 0.03* | −0.53 ± 0.35 | 0.13 | −0.89 ± 0.50 | 0.08 |
| Neutral valence scores | −0.17 ± 0.24 | 0.49 | 0.12 ± 0.27 | 0.65 | −0.86 ± 0.47 | 0.08 |
| MEx (dependent variable) | ||||||
| RMET total scores | −0.04 ± 0.01 | <0.01** | −0.03 ± 0.02 | 0.05 | −0.05 ± 0.02 | 0.03* |
| Positive valence scores | −0.04 ± 0.03 | 0.14 | −0.07 ± 0.04 | 0.07 | −0.01 ± 0.05 | 0.78 |
| Negative valence scores | −0.08 ± 0.03 | <0.01** | −0.07 ± 0.04 | 0.06 | −0.11 ± 0.05 | 0.03* |
| Neutral valence scores | −0.05 ± 0.02 | 0.05 | −0.02 ± 0.03 | 0.42 | −0.10 ± 0.04 | 0.02* |
Abbreviations: see Tables 1 and 2.
aAge, education, gender, disease duration, and LED were adjusted.
bAge, education, disease duration, and LED were adjusted.
*P-value < 0.05. **P-value < 0.01.